Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BDB001
- Development stage
- Phase 3
- Lead developer
- Eikon Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
BDB001, also known as EIK1001, is a clinical-stage immune modulator that acts as an agonist for Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). Originally developed by Seven and Eight Biopharmaceuticals, it was later acquired by Eikon Therapeutics. It is being investigated for the treatment of advanced solid tumors, both as a single agent and in combination with other immunotherapies like pembrolizumab and atezolizumab.
- Other names
- EIK1001EIK-1001EIK 1001BDB001BDB-001BDB 001
02
Targets
TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on BDB001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BDB001.